The Oncology Institute runs 67 clinics delivering cancer care—doctor visits, chemo infusions, and trials—all under one roof, like a one-stop shop for cancer treatment.
Revenue hit USD 0.50B in 2025, but gross margin was only 15.20% and net margin was -12.06%, meaning it loses money on every dollar—no profit engine yet.
Local clinic networks and integrated infusion services create switching costs for patients, but large chains like HCA Healthcare and OneOncology can replicate this model with more capital. Moat is eroding as consolidation intensifies.
Key events, in time order
Multiple sources confirm rebrand and strong Q2 results, expanding value-based oncology pipeline
Insider purchase worth ~$94.9K, plus largest shareholder adding, signaling confidence
Multiple independent sources cite TOI facing CPT code adjustments, with unusual options volume
Repaid Deerfield senior secured convertible via new OrbiMed credit facilities, avoiding dilution; seen as long-awaited catalyst
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
